World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
101
Citations
47473
World Ranking
7851
National Ranking
769

Overview

Paul N. Durrington is affiliated with the University of Manchester in the United Kingdom. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a particular focus on surgery, endocrinology, diabetes and metabolism, cardiology and cardiovascular medicine, cancer research, and economics and econometrics.

Their work covers various topics related to lipoproteins and cardiovascular health, diabetes and cardiovascular risks, lipid metabolism and disorders, cancer and lipids metabolism, health systems with economic evaluations and quality of life, paraoxonase enzyme and polymorphisms, as well as bariatric surgery and related outcomes.

Frequent coauthors in their research include Handrean Soran, Bilal Bashir, Safwaan Adam, Jan Hoong Ho, and Maryam Ferdousi.

Common publication venues for Paul N. Durrington are:

  • Atherosclerosis
  • Current Opinion in Lipidology
  • The Lancet Diabetes & Endocrinology
  • Obesity Surgery
  • Frontiers in Cardiovascular Medicine

Recent notable papers authored or coauthored by Paul N. Durrington include:

  • Paraoxonase 1 and atherosclerosis, 2023, Frontiers in Cardiovascular Medicine
  • Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials, 2022, The Lancet
  • Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis, 2024, The Lancet Diabetes & Endocrinology
  • Improvements in Diabetic Neuropathy and Nephropathy After Bariatric Surgery: a Prospective Cohort Study, 2020, Obesity Surgery
  • Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK, 2020, Atherosclerosis

Best Publications

  • Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

    Helen M Colhoun;D John Betteridge;Paul N Durrington;Graham A Hitman

  • ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)☆☆☆

    Alberico L. Catapano;Zeljko Reiner;Guy De Backer;Ian Graham

  • Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein.

    Michael I. Mackness;Sharon Arrol;Paul N. Durrington

  • Paraoxonase and Atherosclerosis

    P. N. Durrington;B. Mackness;M. I. Mackness

  • Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase

    Michael I. Mackness;Sharon Arrol;Caroline Abbott;Paul N. Durrington

  • Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review

    Lee Hooper;Rachel L Thompson;Roger A Harrison;Carolyn D Summerbell

  • Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins: A Meta-analysis

    S. Matthijs Boekholdt;Benoit J. Arsenault;Samia Mora;Terje R. Pedersen

  • ESC/EAS Guidelines for the management of dyslipidaemias

    Alberico L. Catapano;Željko Reiner;Guy De Backer;Ian Graham

  • LMNA, encoding lamin A/C, is mutated in partial lipodystrophy.

    Sue Shackleton;David J. Lloyd;Stephen N.J. Jackson;Richard Evans

  • Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

    Jane Armitage;Colin Baigent;Elizabeth Barnes;D John Betteridge

  • Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins.

    Michael I. Mackness;Bharti Mackness;Paul N. Durrington;Philip W. Connelly

  • Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus

    Michael I. Mackness;Derek Harty;Deepak Bhatnagar;Peter H. Winocour

  • Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.

    P J Barter;C M Ballantyne;R Carmena;M Castro Cabezas

  • Paraoxonase Status in Coronary Heart Disease Are Activity and Concentration More Important Than Genotype

    Bharti Mackness;Gershan K. Davies;Wajdi Turkie;Evelyn Lee

  • HDL, its enzymes and its potential to influence lipid peroxidation

    Michael I. Mackness;Paul N. Durrington

  • LOW PARAOXONASE ACTIVITY PREDICTS CORONARY EVENTS IN THE CAERPHILLY PROSPECTIVE STUDY

    Bharti Mackness;Paul Durrington;Patrick McElduff;John Yarnell

  • Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: A prospective registry study

    Andrew Neil;Jackie Cooper;John Betteridge;Nigel Capps

  • Serum Paraoxonase Activity, Concentration, and Phenotype Distribution in Diabetes Mellitus and Its Relationship to Serum Lipids and Lipoproteins

    Caroline A. Abbott;Michael I. Mackness;Sudhesh Kumar;Andrew J. Boulton

  • Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification

    Bharti Mackness;Michael I Mackness;Sharon Arrol;Wajdi Turkie

  • Randomised controlled trial evaluating cardiovascular screening and intervention in general practice: principal results of British family heart study

    D A Wood;A L Kinmonth;G A Davies;J Yarwood

Frequent Co-Authors

Helen M. Colhoun
Helen M. Colhoun University of Edinburgh
Graham A. Hitman
Graham A. Hitman Queen Mary University of London
Rayaz A. Malik
Rayaz A. Malik Weill Cornell Medical College in Qatar
David R. Wood
David R. Wood Monash University
Steve E. Humphries
Steve E. Humphries University College London
Dorairaj Prabhakaran
Dorairaj Prabhakaran Centre for Chronic Disease Control
Andrew J.M. Boulton
Andrew J.M. Boulton University of Manchester
Robert A. Hegele
Robert A. Hegele University of Western Ontario
Chris J. Packard
Chris J. Packard Glasgow Royal Infirmary

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying medicine in the USA, there are several alternative and complementary pathways in healthcare you may also want to explore online. For example, administrative roles are in high demand, and medical billing and coding schools online provide accessible options to quickly enter the medical field with strong earning potential.

Nursing remains a popular healthcare career, but admission requirements can be a challenge. Fortunately, you can consider a nursing school without teas test which streamlines the application process and allows you to start sooner. For those aiming to move into leadership roles, an online healthcare management degree offers flexibility and a fast track to management positions in hospitals and clinics.

If you’re a registered nurse planning to advance clinically, pursuing an adn to fnp bridge can help you become a Family Nurse Practitioner without repeating basic coursework. All these pathways offer dynamic career growth and reflect the evolving landscape of healthcare education.

Best Scientists Citing Paul N. Durrington

Trending Scientists

Recently Published Articles